SREBF2 and leukemia: Similar to our findings with SREBP2, we detected a significantly higher RORγ expression in both CD34+ HSPCs and our CRISPR/Cas9 t(4;11) leukemia cells compared to PBMCs and differentiated HSPCs (CD34−) under myeloid culture systems (Fig. 1H).